Compare · BDX vs MCK
BDX vs MCK
Side-by-side comparison of Becton Dickinson and Company (BDX) and McKesson Corporation (MCK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. BDX focuses on Medical/Dental Instruments, while MCK focuses on Other Pharmaceuticals.
- MCK is the larger of the two at $94.41B, about 2.4x BDX ($40.00B).
- Over the past year, BDX is down 15.6% and MCK is up 9.2% - MCK leads by 24.8 points.
- MCK has been more active in the news (25 items in the past 4 weeks vs 6 for BDX).
- Both have 25 recent analyst ratings on file.
- Company
- Becton Dickinson and Company
- McKesson Corporation
- Price
- $145.20-0.23%
- $785.59+0.78%
- Market cap
- $40.00B
- $94.41B
- 1M return
- +1.21%
- +3.26%
- 1Y return
- -15.62%
- +9.17%
- Industry
- Medical/Dental Instruments
- Other Pharmaceuticals
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 6
- 25
- Recent ratings
- 25
- 25
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
McKesson Corporation
McKesson Corporation provides healthcare supply chain management, retail pharmacy, community oncology and specialty care, and healthcare information solutions in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment offers CoverMyMeds solution to help patients get the medications; RelayHealth, a workflow solution; RxCrossroads solution for therapies and interventions to biopharma manufacturers; and McKesson Prescription Automation, a customized pharmacy automation technology; and Multi-Client Central Fill as a Service, a pharmacy. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Latest BDX
- EVP & Pres Med.Essntl&BioPharm Garrison Michael David sold $166,628 worth of shares (1,100 units at $151.48) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 14,272 units (SEC Form 4)
- Chairman, CEO and President Polen Thomas E Jr exercised 20,209 shares at a strike of $126.16, returned $2,549,587 worth of shares to the company (17,445 units at $146.15) and sold $404,511 worth of shares (2,764 units at $146.35) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 110,163 units (SEC Form 4)
- EVP and President, BDI Menziuso Peter was granted 14,258 shares (SEC Form 4)
- New insider Menziuso Peter claimed no ownership of stock in the company (SEC Form 3)
- Becton Dickinson and Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- EVP, Chief Revenue Officer Feld Michael sold $11,051 worth of shares (75 units at $147.35) as part of a pre-agreed trading plan, decreasing direct ownership by 0.35% to 21,084 units (SEC Form 4)
- SEC Form SD filed by Becton Dickinson and Company
- SEC Form CERT filed by Becton Dickinson and Company
- BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System
- Becton Dickinson and Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
Latest MCK
- SEC Form DEFA14A filed by McKesson Corporation
- SEC Form DEF 14A filed by McKesson Corporation
- McKesson Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Chief Executive Officer Tyler Brian S. sold $3,760,827 worth of shares (4,929 units at $763.00) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 22,845 units (SEC Form 4)
- SVP, Controller & CAO Rutledge Napoleon B Jr sold $101,612 worth of shares (133 units at $764.00) as part of a pre-agreed trading plan, decreasing direct ownership by 17% to 632 units (SEC Form 4)
- EVP, Chief Strategy & BDO Rodgers Thomas L sold $604,420 worth of shares (822 units at $735.30) as part of a pre-agreed trading plan, decreasing direct ownership by 27% to 2,268 units (SEC Form 4)
- EVP & Chief HR Officer Smith Leann B sold $1,331,255 worth of shares (1,810 units at $735.50) as part of a pre-agreed trading plan, decreasing direct ownership by 27% to 4,798 units (SEC Form 4)
- McKesson Closes Strategic Investment with Apollo Funds for Minority Interest in Medical-Surgical Solutions
- SEC Form 4 filed by EVP & CFO Cheung Kenny K
- SEC Form 3 filed by new insider Cheung Kenny K